Craniosynostosis Archives - Carey Danis & Lowe

UCLA SSRI Study Examines Pregnancy & Drugs

By | Lexapro, Paxil, Pharmaceutical litigation, Prozac, Uncategorized, Zoloft

ssri_birth_defectsA UCLA study published in December 2014 examined the use of selective serotonin reuptake inhibitors, or SSRIs, during pregnancy. The researchers used lab mice to observe the effects of SSRI exposure in the womb, and how it impacts adult mice.

They observed that adult mice exposed to the SSRI, Lexapro, experienced a permanent change in serotonin transmission, whereas those adult mice exposed to Prozac in the womb, showed no signs of this permanent change.

The UCLA study examined a new side of SSRIs and pregnancy, one documenting the longterm implications of SSRI exposure in the womb, rather than the immediate.

The immediate implications of SSRI exposure in the womb, to a certain degree, are already known. Children have been born with life-changing congenital birth defects. These birth defects include atrial septal defects, ventricular septal defects, Omphalocele, Craniosynostosis, and persistent pulmonary hypertension of the newborn (PPHN).

Carey Danis & Lowe Can Help

Carey Danis & Lowe is a national law firm with a strong reputation for expertly assisting families through the challenges of recovering losses after a child has been born with SSRI birth defects. Our defective drug lawyers understand the pain and suffering these children and their families endure, and are available to help.

Explore your legal options and compensation eligibility today during a free, no-obligation case evaluation.

Contact Carey Danis & Lowe by phone at 800.721.2519, or submit a confidential personal injury claim form.

We look forward to offering you and your family any assistance that we can.

Paxil Birth Defects Mass Tort Update, Approaching End

By | Paxil, Pharmaceutical litigation, Uncategorized

SSRI Antidepressant Paxil Birth Defects LitigationThe Paxil birth defects mass tort currently being heard in a Philadelphia court is approaching conclusion. The mass tort once comprised approximately 1,000 lawsuits, and currently includes only two, according to an article recently published by Law.com.

A majority of the lawsuits in the Paxil mass tort were settled without a trial. Even so, a substantial number of these lawsuits were either transferred from the state court in Philadelphia to a federal court, or were sent back to their state of origin.

With legal proceedings wrapping up in Philadelphia, St. Louis is now considered the focal point for Paxil birth defects lawsuits, as a sizable number of cases are currently pending there.

Carey Danis & Lowe, a law firm headquartered in St. Louis, is hoping for a swift conclusion in these cases, as the lives of so many families have been negatively impacted.

Women across the country, along with their families, have filed lawsuits against the manufacturer of Paxil, GlaxoSmithKline, alleging that use of their SSRI antidepressant during pregnancy resulted in their children developing life-altering birth defects. Paxil birth defects range from heart defects, such as a hole in the heart, to persistent pulmonary hypertension of the newborn (PPHN) to Craniosynostosis. A more comprehensive list of birth defects can be reviewed here: Paxil birth defects list.

Carey Danis & Lowe Represents Victims of Paxil

Carey Danis & Lowe specializes in defective drug litigation, and currently represents women and their families in Paxil birth defects lawsuits. If you or a loved one used Paxil during pregnancy, and your child was born with a birth defect, we encourage you to begin reviewing your legal options and compensation eligibility with one of our defective drug lawyers today.

Our lawyers are available to listen to your Paxil story. Contact Carey Danis & Lowe by phone at 800.721.2519, or complete a confidential personal injury claim form.

Zoloft Birth Defects Lawsuit Review

By | Pharmaceutical litigation, Uncategorized, Zoloft

SSRI Antidpressant Zoloft Birth Defects LitigationA court document filed in July in the Zoloft multidistrict litigation (MDL) collected the latest information on Zoloft birth defects lawsuits pending across the U.S. According to the court document, in addition to the consolidated cases in the Pennsylvania Zoloft MDL, there are pending lawsuits in California, Illinois, Missouri, New York, and West Virginia.

In state courts across California, plaintiffs filed a total of 7 lawsuits in July 2013. There three cases pending in Illinois courts, with one lawsuit in St. Clair county involving eight families, and a 38 family case in the Southern District of Illinois.

In Missouri, there are three Zoloft lawsuits pending in courts, and in New York, there are five lawsuits pending in Oneida County and New York County. There is one case pending in the Circuit Court of Wayne County in West Virginia.

As of July 16, 2013, there are over 400 Zoloft lawsuits pending in the Zoloft MDL.

The Zoloft MDL is being heard in the U.S. District Court for the Eastern District of Pennsylvania, and is being overseen by U.S. District Judge Cynthia M. Rufe. The Zoloft MDL is In re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation, MDL No. 2342. The first bellwether case is scheduled to come to trial in October 2014.

Women and their families have filed Zoloft birth defects lawsuits claiming that the use of Zoloft during pregnancy led to congenital birth defects. The most commonly reported birth defects are congenital heart defects, Omphalocele, Craniosynostosis, and persistent pulmonary hypertension of the newborn (PPHN). Visit the Zoloft birth defects information page for a complete Zoloft birth defects list.

Carey Danis & Lowe Zoloft birth defects lawyers work diligently to win justice for those who have been injured by negligent pharmaceutical companies. Our team of legal and medical experts are here to help. If you took Zoloft while pregnant, and your child was born with birth defects, depend upon Carey Danis & Lowe to win you justice and resolution to your troubles and suffering.

Contact Carey Danis & Lowe for a free legal evaluation and for medical advice by calling 800.721.2519, or by submitting a personal injury claim form.

Wellbutrin Claims and Topamax Claims on the Rise at Carey Danis & Lowe

By | Pharmaceutical litigation, Topamax, Uncategorized, Wellbutrin

Published October 31, 2012 by PR Web

St. Louis, MO (PRWEB) October 31, 2012

Wellbutrin Claims and Topamax Claims on the Rise at Carey Danis & LowePharmaceutical product liability lawyers at Carey Danis & Lowe have announced that they are undertaking an investigation into Wellbutrin claims. Attorneys at Carey Danis & Lowe are asking that individuals and families contact the law firm if they feel their child, or the child of a loved one, was born with a congenital heart defect due to the use of Wellbutrin during pregnancy.

Wellbutrin is a drug manufactured by GlaxoSmithKline, and is used in to treat patients suffering from depression as well as seasonal affective disorder (SAD), attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has classified Wellbutrin as a Pregnancy Category C drug.

Wellbutrin allegedly causes birth defects include oral defects, congenital heart defects, Craniosynostosis, Omphalocele, and Persistent Pulmonary Hypertension of the Newborn (PPHN).

In addition, lawyers at Carey, Danis and Lowe are taking cases related to the use the use of Topamax. Prescribed to patients suffering from epilepsy and migraine headaches, Topamax is a drug manufactured by Ortho-McNeil-Janssen Pharmaceuticals Inc. Allegedly, Topamax can cause congenital oral defects in unborn children. The FDA has categorization Topamax as a Pregnancy Category D drug. Potential oral birth defects caused by Topamax include the development of a cleft lip and cleft palette.

In past pharmaceutical product liability cases, attorneys at Carey Danis & Lowe have aided plaintiffs in winning cases against pharmaceutical giants like GlaxoSmithKline and Ortho-McNeil-Janssen Pharmaceuticals Inc.

If a newborn baby has suffered birth defects allegedly caused by exposure in the womb to either Wellbutrin or Topamax, contact an attorney at Carey Danis & Lowe at 800.721.2519, or submit a claims form about filing a Wellbutrin lawsuit or a Topamax lawsuit.

Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect Cases

By | Pharmaceutical litigation, Uncategorized, Zoloft

Zoloft MDL Updates: Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect CasesThe Zoloft Multi-District Litigation No. 2342 being heard in the U.S. District Court for the Eastern District of Pennsylvania has made progress as regards setting the date for the first trial. According to Pre-trial Court Order 15, the first trial is currently scheduled for September 12, 2014. This is a tentative date that is dependent upon completion of all pertinent discovery by both sides.

This same court document from the Zoloft MDL details that by January 11, 2013, both the Defense and the Plaintiff’s counsel must deliver selections pertaining to Initial Discovery Group Cases, which will help in determining which cases enter the Trial Pool Cases.

The court has ordered that selections of cases that are representative enough for Trial Pool Cases should be supplied to the court by March 15, 2013.

According to a December 2012 article published by The Madison Record, there are currently 250 Zoloft cases that have been consolidated into the Pennsylvania MDL. What is more, there remain a number of Zoloft lawsuits pending in state courts that have not yet been consolidated into the MDL. State courts hearing these Zoloft lawsuits include Illinois, Missouri, New York, Pennsylvania, and West Virginia.

Plaintiffs in the Zoloft MDL claim that the use of Zoloft during pregnancy resulted in the development of birth defects in newborn children. These Zoloft birth defects include, but are not limited to, the following:

  • Congenital heart defects
  • Atrial septal defects
  • Ventricular septal defects
  • Omphalocele
  • Craniosynostosis
  • Persistent Pulmonary Hypertension of the Newborn (PPHN)

Zoloft is an anti-depressant drug manufactured by Pfizer. Zoloft is categorized as a selective serotonin re-uptake inhibitor, or SSRI. These types of antidepressants have a strong link to the development of birth defects in children exposed to an SSRI drug while in the womb.

If your newborn child was exposed to the SSRI medication Zoloft while in the womb, and as a result, developed life-altering and health compromising birth defects, you and your child may be entitled to receive recompense for your physical suffering, emotional suffering, and medical expenses.

For more information about filing a Zoloft birth defect lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe. Our pharmaceutical product liability lawyers will provide you with a free legal consultation about your Zoloft case. Call a Zoloft lawyer at Carey Danis & Lowe today at 800.721.2519.

Antidepressant Wellbutrin Linked to Birth Defects

By | Pharmaceutical litigation, Uncategorized, Wellbutrin

Published October 23, 2012 by LawsuitInformation.org

Antidepressant Wellbutrin Linked to Birth DefectsManufactured by pharmaceutical giant GlaxoSmithKline, Wellbutrin is an antidepressant drug that has been linked to congenital birth defects. The U.S. Food and Drug Administration (FDA) approved the antidepressant medication Wellbutrin (bupropion) in order to treat depression.

Due to the increasing occurrences of life-threatening and life-altering birth defects connected with the use of Wellbutrin in pregnant mothers, the FDA has categorized Wellbutrin as a pregnancy category C drug. Unlike many antidepressants on the market that block serotonin, Wellbutrin is categorized as a norepinephrine and dopamine re-uptake inhibitor (NDRI).

Wellbutrin birth defects include, but are not limited to, the following:

  • Cleft lip
  • Cleft palate
  • Congenital cardiac defects
  • Atrial Septal Defects (ASD)
  • Ventricular Septal Defects (VSD)
  • Persistent Pulmonary Hypertension of the Newborn(PPHN)
  • Craniosynostosis
  • Omphalocele

In 2010, a Wellbutrin study was published in the American Journal of Obstetrics and Gynecology that pointed to data showing a significant link between the use of Wellbutrin by a pregnant woman, especially during the first trimester of pregnancy, and the development of congenital birth defects, in particular cardiac complications and malformations.

Termination of Wellbutrin use during pregnancy will most certainly benefit an unborn child as a result of Wellbutrin’s connection to birth defects. However, discontinued use of an antidepressant drug by a pregnant woman must be discussed with a physician in order to weigh the risks of continued use on the unborn child and terminated use on the expectant mother.

It is also important to note that following pregnancy, if a nursing mother decides to begin use of Wellbutrin, such a decision is important to discuss with a physician. It has been understood that Wellbutrin is a drug that can present itself in breast milk, and therefore, can lead to injurious health effects on a newborn.

If your newborn has suffered from birth defects correlated to exposure to Wellbutrin in the womb, submit your claim to an experienced pharmaceutical litigation lawyer at Carey Danis & Lowe. Also, contact a pharmaceutical product liability attorney at Carey Danis & Lowe at 800.721.2519 for a free legal consultation about filing a Wellbutrin lawsuit. It is important to hold GlaxoSmithKline accountable for their negligence to inform the public about Wellbutrin’s link to the development of life-threatening congenital birth defects.

Our lawyers at Carey Danis & Lowe are committed to providing you the legal support and counsel you need to win a Wellbutrin lawsuit and receive compensation for your pain, suffering, and financial losses.

Zoloft Lawsuit Underscores Parents’ Heartbreak

By | Pharmaceutical litigation, Uncategorized, Zoloft

Posted March 18, 2012 on LawsuitInformation.org

St. Louis, MO: The recent filing of a Zoloft birth defects lawsuit underscores the pain, heartbreak and frustration evident in the plaintiffs—parents of innocent children who came into the world saddled with life-altering defects allegedly at the behest of the SSRI antidepressant, Zoloft.

It is no secret that antidepressants have been a success for pharmaceutical companies. They also represent important options in the tool belts and treating protocols of psychiatrists and medical doctors, for the treatment of depression.

However, the link between Selective Serotonin Reuptake Inhibitors and birth defects, such as Zoloft cleft palate, have driven the parents of 18 children suffering from Zoloft defects to the courts.

Reuters reports that the lawsuit filed by plaintiff Shainyah Lancaster et al last month in St. Louis, accuses Zoloft manufacturer Pfizer of suppressing information to the medical community and the public at large as to the risks associated with Zoloft when used by women of childbearing age. The lawsuit further alleges that Pfizer knew or should have known of the existence of SSRI studies, which suggested a greater risk of congenital birth defects in concert with a Zoloft pregnancy.

The Zoloft birth defects lawsuit further alleges that Pfizer was aware that Zoloft was being prescribed to pregnant women by their doctors, but that Pfizer failed to warn the medical community about the risks.

Zoloft has been the center of controversy for some time. Dr. Sidney Wolfe, of the consumer advocacy group Public Citizen, took Pfizer to task for promoting Zoloft for unapproved uses. In a statement released in October 1996, Wolfe referenced a communiqué directed to Pfizer from the US Food and Drug Administration (FDA) in August of that year, chastising Pfizer for promoting Zoloft for use in cardiac patients with depression, amongst other unapproved uses.

More recently, Peter Breggin MD, blogging in the Huffington Post on June 28, 2007, noted the spin that often accompanies the release of data. He noted that headlines and media reports surrounding the release of data from a 2007 study seemed to downplay the risks associated with SSRI drugs—Zoloft among them—even though, according to Breggin, “several severe birth defects were doubled or nearly tripled in frequency when SSRIs were taken in the first trimester. This combined with the other known toxic effects of SSRIs, including brain damage and dysfunction, make these drugs contraindicated in pregnancy.”

One of those defects—Zoloft craniosynostosis—was described in Dr. Breggin’s blog post as “the premature closing of one or more sutures or fibrous joints knitting the bones of the infant’s skull.” He noted that craniosynostosis occurs in about four per 10,000 births according to the National Institutes of Health. “A 2.8 times greater occurrence of this condition will cause 2,305 more US babies to be born each year with this birth defect as a result of their mothers taking SSRIs in the first trimester of pregnancy.”

The particular afflictions of the 18 children who allegedly suffer from Zoloft birth defects were not identified in the news reports. However, regardless of the defect suffered by the Zoloft child—Zoloft PPHN, cleft palate or Zoloft heart defects—it is assumed that their parents are facing a lifetime of stormy seas as the result of having a Zoloft newborn. As Zoloft parents face reality, they equally expect Pfizer to face the music.

Zoloft Side Effects – Birth Defects in Detail

By | Pharmaceutical litigation, Uncategorized, Zoloft

Published April 20, 2012 on LawsuitInformation.org

Side effects from Zoloft, a brand name antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs), may cause life-altering and potentially life-threatening side effects / birth defects for newborns of women who took the drug during pregnancy. If your child has been harmed, contact Carey Danis & Lowe immediately. We represent hundreds of families that have been affected by Zoloft Birth Defects.

If you are looking for a compassionate law firm that is experienced with defective drugs and the adverse effects of Zoloft, contact us. Our PPHN lawyers are investigating the dangers of this drug and the possible link to the birth defect PPHN (Pulmonary Hypertension in Newborns). We are here to answer any questions you may have and help you navigate through the process of filing a Zoloft lawsuit.


Newborns exposed to Zoloft and other SSRIs during the first trimester of pregnancy are at risk of developing several different kinds of side effects (birth defects), including neural tube defects, cleft lip, PPHN side effects, and heart defects. Keep reading to review a complete list of the potentially dangerous side effects caused by Zoloft in newborns.

Neural Tube Defect Side Effects:

Neural tube birth defects affect the brain and spinal cord. Also called cleft spine or open spine, it is the underdevelopment of the fetal spinal column (neural tube). In an embryo, this region begins as a flat surface, and about 28 days after conception, the flat region rolls into a tube. Neural tube defects occur when this tube does not close completely, leaving an opening at the skull or vertebrae. Neural tube defects cause paralysis, incontinence, learning difficulties, loss of sensation in parts of the body, developmental delays, lack of coordination, and lack of concentration.

Omphalocele Side Effects:

An omphalocele is a birth defect caused by underdeveloped abdominal wall muscles that leaves an opening in the midgut. It causes the intestines and other organs, covered only by a thin sac, to protrude outside of this opening. While the problem can typically be corrected with surgery, many newborns with omphalocele will have additional serious side effects, including heart defects. Some of these side effects can be potentially fatal.

Cleft Lip Side Effects:

A cleft lip is a birth defect where the lip does not fuse properly during the early stages of fetal development. This side effect is characterized by a vertical fissure in one or both sides of the upper lip causes a number of difficulties, including problems with feeding, missing or malformed teeth, speech and language delay, chronic ear infections, hearing loss, and socialization.

Cleft Palate Side Effects:

A cleft palate is a birth defect in which the roof of the mouth fails to close completely in utero (at about the 6th to 9th week of pregnancy), and as a result, connects the mouth directly with the nasal cavity. Infants with a cleft palate often struggle with serious complications, including recurring ear infections, hearing loss, feeding difficulties, missing or misaligned teeth, and delays in speech and language development.

Craniosynostosis Side Effects:

Craniosynostosis is a side effect characterized by the premature fusion of an infant’s cranial sutures, the joints between the bones of the skull. The elasticity of the cranium is essential in the skull’s ability to expand in order to accommodate normal brain growth. Because the suture(s) close early, it constricts the growth of the skull (as well as the brain) and results in an abnormally shaped head. Besides irregular appearance, infants with craniosynostosis side effects may also suffer from increased intracranial pressure, seizures, and developmental delays.

Heart Defect Side Effects:

Heart defect side effects involve the structure of the heart or the blood vessels surrounding the heart. It can either obstruct blood flow in the heart or cause irregular blood flow through the heart. While some heart defects are minor and require little to no treatment, others are life-threatening and require immediate medical care in order to avoid severe consequences.

Limb Defect Side Effects:

Congenital limb defects are side effects characterized by the improper formation of an entire limb, or portion of a limb, in utero. Limb defects can involve the hand, arm, foot, leg, toes or fingers, and can present as undergrowth, overgrowth, complete absence, duplication, webbing, or as a constricting band syndrome (premature rupture of the amniotic sac that causes membranes or bands to entangle the fetus, which cuts off blood flow and tissue growth). One of the most common limb defects is club foot, a side effect in which a child is born with one or both feet smaller than normal and internally rotated at the ankle.

PPHN Side Effects:

PPHN, or persistent pulmonary hypertension of the newborn, is a side effect that causes high blood pressure in the lungs, which keeps the lungs from relaxing to allow blood to flow through properly. As a result, oxygen does not reach the bloodstream when the child breathes. Even with treatment, an infant with PPHN may continue to receive an insufficient amount of oxygen to his or her vital organs and tissues. This can potentially result in shock, seizures, heart failure, multiple organ failure, and even death.

Anal Atresia Side Effects:

Anal atresia, also referred to as imperforate anus or anal rectal malformation, is a side effect which can cause the following complications: the opening to the rectum does not properly connect to the colon; the rectum may have openings to the urethra, the bladder, the vagina, penis or scrotum; or the anus may be narrowed or missing. Although most infants with anal atresia make a full recovery after surgery, others may continue to suffer from difficulties like bowel control, constipation, and intestinal blockage. Other affected infants may experience additional side effects, particularly those of the genitals, spine or urinary tract.